Nobu OSHIMA

Dr. Nobu OSHIMA


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NONobu OSHIMA
Nobu OSHIMA
YYYasuhiro Yamada
Yasuhiro Yamada
SNSatoshi Nagayama
Satoshi Nagayama
KKKenji Kawada
Kenji Kawada
SHSuguru Hasegawa
Suguru Hasegawa
TATakashi Aoi
Takashi Aoi
Cancer stem cells (CSCs) are considered to be responsible for the dismal prognosis of cancer patients. However, little is known about the molecular mechanisms underlying the acquisition and maintenance of CSC properties in cancer cells because of their rarity in clinical samples. We herein induced CSC properties in cancer cells using defined factors. We retrovirally introduced a set of defined factors (OCT3/4, SOX2 and KLF4) into human colon cancer cells, followed by culture with conventional serum-containing medium, not human embryonic stem cell medium. We then evaluated the CSC properties in the cells. The colon cancer cells transduced with the three factors showed significantly enhanced CSC properties in terms of the marker gene expression, sphere formation, chemoresistance and tumorigenicity. We designated the cells with CSC properties induced by the factors, a subset of the transduced cells, as induced CSCs (iCSCs). Moreover, we established a novel technology to isolate and collect the iCSCs based on the differences in the degree of the dye-effluxing activity enhancement. The xenografts derived from our iCSCs were not teratomas. Notably, in contrast to the tumors from the parental cancer cells, the iCSC-based tumors mimicked actual human colon cancer tissues in terms of their immunohistological findings, which showed colonic lineage differentiation. In addition, we confirmed that the phenotypes of our iCSCs were reproducible in serial transplantation experiments. By introducing defined factors, we generated iCSCs with lineage specificity directly from cancer cells, not via an induced pluripotent stem cell state. The novel method enables us to obtain abundant materials of CSCs that not only have enhanced tumorigenicity, but also the ability to differentiate to recapitulate a specific type of cancer tissues. Our method can be of great value to fully understand CSCs and develop new therapies targeting CSCs.

12 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YAYuki Aisu
Yuki Aisu
NONobu OSHIMA
Nobu OSHIMA
FHFuminori Hyodo
Fuminori Hyodo
AEAbdelazim Elsayed Elhelaly
Abdelazim Elsayed Elhelaly
AMAkihiko Masuo
Akihiko Masuo
KOKazutaka Obama
Kazutaka Obama
Pyruvate is situated at the intersection of oxidative phosphorylation (OXPHOS) and glycolysis, which are the primary energy-producing pathways in cells. Cancer therapies targeting these pathways have been previously documented, indicating that inhibiting one pathway may lead to functional compensation by the other, resulting in an insufficient antitumor effect. Thus, effective cancer treatment necessitates concurrent and comprehensive suppression of both. However, whether a metabolic switch between the metabolic pathways occurs in colorectal and gastric cancer cells and whether blocking it by inhibiting both pathways has an antitumor effect remain to be determined. In the present study, we used two small molecules, namely OXPHOS and glycolysis inhibitors, to target pyruvate metabolic pathways as a cancer treatment in these cancer cells. OXPHOS and glycolysis inhibition each augmented the other metabolic pathway in vitro and in vivo. OXPHOS inhibition alone enhanced glycolysis and showed antitumor effects on colorectal and gastric cancer cells in vitro and in vivo. Moreover, glycolysis inhibition in addition to OXPHOS inhibition blocked the metabolic switch from OXPHOS to glycolysis, causing an energy depletion and deterioration of the tumor microenvironment that synergistically enhanced the antitumor effect of OXPHOS inhibitors. In addition, using hyperpolarized 13C-magnetic resonance spectroscopic imaging (HP-MRSI), which enables real-time and in vivo monitoring of molecules containing 13C, we visualized how the inhibitors shifted the flux of pyruvate and how this dual inhibition in colorectal and gastric cancer mouse models altered the two pathways. Integrating dual inhibition of OXPHOS and glycolysis with HP-MRSI, this therapeutic model shows promise as a future "cancer theranostics" treatment option.

1 January 2009 in Case Reports in Gastroenterology
Verified
Journal Article
Open access
PDF file
NONobu OSHIMA
Nobu OSHIMA
HTHiroaki Terajima
Hiroaki Terajima
RHRyo Hosotani
Ryo Hosotani
Hepatic epithelioid hemangioendothelioma (HEHE) is a rare neoplasm of vascular origin. The clinical presentation of HEHE is variable, and the therapeutic criteria are still unclear since its natural history is unpredictable. A 53-year-old woman was admitted to our hospital because she had a 2.5-cm diameter nodule in the segment V of the liver. She had undergone segmental hepatectomy for solitary HEHE in segment VII 10 years before. There had been no recurrence for the 10 years after the first operation. The tumor was diagnosed as a new lesion of HEHE by percutaneous needle liver biopsy, and thereafter repeated hepatectomy was performed. HEHE seems to be resistant to chemotherapy and radiotherapy. Either surgical resection or orthotopic liver transplantation is generally recommended as a curative treatment for this disease. However, HEHE tends to be detected in multiple lesions, and localized disease is rare. Therefore, the chance of resection is very low. Some reports do not recommend local resection because of early aggressive tumor spread even after curative resection. We herein demonstrate a rare case of HEHE in a patient who underwent repeated hepatectomy for a solitary lesion and who survived for 17 years. It is concluded that surgical resection is one of the most effective treatments for a solitary form of HEHE.

1 January 2025 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
KTKan Toriguchi
Kan Toriguchi
SKSatoshi Kaihara
Satoshi Kaihara
MNMasatoh Narita
Masatoh Narita
TITatsuki Ishikawa
Tatsuki Ishikawa
MSMasashi Saji
Masashi Saji
KUKenji Uryuhara
Kenji Uryuhara

5 March 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NONobu OSHIMA
Nobu OSHIMA
YAYuki Aisu
Yuki Aisu
AMAkihiko Masuo
Akihiko Masuo
YTYoichi Takakusagi
Yoichi Takakusagi
TKTatsuya Kawai
Tatsuya Kawai
Introduction: Colorectal cancer (CRC) remains a major global health burden, with an increasing emphasis on understanding its metabolic landscape and identifying novel theranostic approaches. In recent years, hyperpolarized 13C-MRI, an innovative imaging technology that visualizes the metabolic characteristics of cancer tissue and metabolic changes induced by treatment, has been developed, leading to a surge in research reports on its applications. The advancement of scientific and technological approaches to understanding cancer metabolism has been remarkable, highlighting the rapid progress in this field. This Research Topic explores how cancer metabolism can be both targeted for therapy and monitored for disease progression, advancing the field of personalized oncology. The five articles published within this topic collectively provide significant contributions to the understanding of metabolic reprogramming in CRC and its potential applications in clinical practice.The first article, Multi-omics analyses of glucose metabolic reprogramming in colorectal cancer (Huang et al., 2023), presents a comprehensive multi-omics approach to dissect the metabolic pathways underlying CRC progression. This study highlights how glucose metabolic reprogramming (GMR) is intricately linked with epithelial-mesenchymal transition (EMT) and metastatic potential. By integrating genomics, proteomics, and metabolomics data, the authors identify novel metabolic markers and propose the CEA/blood glucose ratio as a potential diagnostic tool for CRC liver metastasis.The second article, Development and validation of a risk prediction model for sarcopenia in patients with colorectal cancer (Zhang and Zhu, 2023), addresses the often-overlooked issue of sarcopenia in CRC patients. By constructing a predictive nomogram based on clinical and metabolic parameters, the study offers a valuable tool for early identification of high-risk patients, enabling timely nutritional and therapeutic interventions to improve patient outcomes.The third article, Can proline dehydrogenase-a key enzyme involved in proline metabolism-be a novel target for cancer therapy? (Xu et al., 2023), explores the dual role of proline dehydrogenase (PRODH) in cancer metabolism. While PRODH can induce apoptosis through reactive oxygen species (ROS) signaling, it also promotes tumor survival under hypoxic conditions. This review provides an in-depth discussion on the potential of targeting PRODH as a novel therapeutic strategy for CRC.The fourth article, Fer governs mTORC1 regulating pathways and sustains viability of pancreatic ductal adenocarcinoma cells (Schrier et al., 2024), investigates the regulatory role of the tyrosine kinase Fer in metabolic signaling pathways. Although the study primarily focuses on pancreatic ductal adenocarcinoma, its findings have broader implications for CRC. The study highlights how Fer-mediated regulation of mTORC1 activity influences cellular metabolism, paving the way for potential crosscancer therapeutic applications.The final article, The use of nutrigenomics and nutritional biomarkers with standard care of long-term recurrent metastatic rectal cancer: a case report (Brinkman et al., 2024), presents a compelling case study demonstrating the role of personalized nutrition in CRC management. By integrating nutrigenomics and monitoring key biomarkers such as folate, vitamin B12, and vitamin D, the study underscores the importance of a multidisciplinary approach to improving long-term patient survival.Collectively, these articles underscore the evolving landscape of CRC research, emphasizing metabolic targeting and theranostics as essential components of personalized cancer treatment. From fundamental metabolic pathways to clinical applications, this Research Topic provides a foundation for future studies aimed at optimizing therapeutic strategies for CRC.Regrettably, while this collection provides numerous valuable discussions and insights, it does not include a dedicated discourse on the application of hyperpolarized 13C-MRI. The imaging technology represents a crucial element in the development of new cancer therapies, and further exploration is required to fully realize its potential applications. We look forward to future submissions that introduce novel imaging techniques and fresh perspectives on this technology.We extend our sincere appreciation to all contributing authors, reviewers, and researchers who played a pivotal role in the development of this Research Topic. Their dedication and expertise have made it possible to advance the discourse in oncology, and we look forward to seeing how these findings inspire new research endeavors.I express my gratitude to all contributors who have enriched this theme with their expertise and insights. Finally, I would like to thank co-editors, Professors Yoichi Takakusagi and Tatsuya Kawai. And, I aslso thank to Professors Masayuki Matsuo, Fuminori Hyodo, Neckers Leonard and Murali C. Krishna for fruitful discussion.

8 July 2025 in Asian Journal of Surgery
Verified
Journal Article
Open access
SMShotaro Matsuda
Shotaro Matsuda
NONobu OSHIMA
Nobu OSHIMA
SKShigeshi Kohno
Shigeshi Kohno
SKSatoshi Kaihara
Satoshi Kaihara